Indication
Aggressive B-Cell Lymphoma
2 clinical trials
6 products
Clinical trial
A Phase 1 Study to Assess Safety and Tolerability of Odronextamab (REGN1979) an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, and Cemiplimab (REGN2810), an Anti-Programmed Death-1 Monoclonal Antibody in Patients With B-Cell Malignancies (CLIO-1)Status: Recruiting, Estimated PCD: 2026-12-25
Product
odronextamabProduct
cemiplimabClinical trial
Improvement of Outcome and Reduction of Toxicity in Elderly Patients With CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination With Vitamin D SubstitutionStatus: Completed, Estimated PCD: 2024-01-18
Product
VincristineProduct
Liposomal VincristineProduct
Ricover-scheme rituximabProduct
Rituximab